Continuous infusion 5-fluorouracil (5FU) as a novel treatment for heavily pretreated prostate cancer patients: An update.

被引：4
|
作者：
Manogue, Charlotte
Cotogno, Patrick
Moses, Marcus Marie
Barata, Pedro C.
Layton, Jodi Lyn
Sartor, A. Oliver
Lewis, Brian E.
机构：
[1] Tulane Univ, Ctr Canc, New Orleans, LA 70118 USA
[2] Tulane Canc Ctr, Off Clin Res, New Orleans, LA USA
[3] Tulane Univ, New Orleans, LA 70118 USA
[4] Tulane Univ, Sch Med, 1430 Tulane Ave, New Orleans, LA 70112 USA
[5] Tulane Med Sch, New Orleans, LA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.319
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
319
引用
收藏
页数：1
相关论文
共 50 条
  • [1] 5FU Continuous Infusion in Heavily Pretreated Advanced Breast Cancer Patients
    Regierer, Anne C.
    Reinecke, Franziska
    Weigel, Andrea
    Dieing, Annette
    Lehenbauer-Dehm, Silvia
    Schwarzlose-Schwarck, Sandra
    Possinger, Kurt
    Eucker, Jan
    ONKOLOGIE, 2011, 34 (12): : 696 - 700
  • [2] Continuous infusion fluorouracil (5FU) in heavily pre-treated mCRPC patients.
    Manogue, Charlotte
    Moses, Marcus Marie
    Lewis, Brian E.
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [3] LEVELS OF 5-FLUOROURACIL (5FU) IN PLASMA OF PATIENTS TREATED BY DRUG INFUSION
    HILLCOAT, BL
    MCCULLOCH, PB
    FIGUEREDO, A
    ROSENFELD, J
    KAWAI, M
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1976, 17 (MAR): : 199 - 199
  • [4] Phase II study of oxaliplatin (OHP) and protracted 5-fluorouracil (5FU) infusion in pretreated metastatic colorectal cancer (MCRC) patients
    Mini, E
    Pinto, C
    Angelelli, B
    Dentico, P
    Piana, E
    Nobili, S
    Gentile, AL
    Scicolone, S
    Mazzei, T
    Martoni, A
    ANNALS OF ONCOLOGY, 2000, 11 : 73 - 73
  • [5] Is there a circadian variation in 5-Fluorouracil (5FU) plasma concentration (Cp) given by continuous infusion?
    Strocchi, E
    Camaggi, CM
    Martoni, A
    Sereni, A
    Pannuti, R
    Pittureri, C
    Cacciari, N
    Zamagni, C
    Pannuti, F
    ANNALS OF ONCOLOGY, 1998, 9 : 51 - 51
  • [6] CONTINUOUS 5-FLUOROURACIL (5FU) INFUSION IN CARCINOMA OF THE PANCREAS - A PHASE-II STUDY
    HANSEN, R
    QUEBBEMAN, E
    RITCH, P
    CHITAMBAR, C
    ANDERSON, T
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1988, 295 (02): : 91 - 93
  • [7] Third line oxaliplatin with leucovorin (LV) and continuous infusion 5-fluorouracil (5FU) in metastatic colorectal cancer.
    Abón, G
    Muñoz, A
    Rubio, I
    Mañé, JM
    Ferreiro, J
    Fernández, R
    Fuente, N
    López-Argumedo, G
    Barceló, R
    Vivanco, GL
    ANNALS OF ONCOLOGY, 2000, 11 : 48 - 49
  • [8] A phase I dose escalation of hydroxyurea (HU) in addition to continuous infusion 5-fluorouracil (5FU) in patients with advanced colorectal cancer
    Last, K
    Lofts, FJ
    Thompson, F
    Mansi, JL
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S14 - S14
  • [9] GENOTOXIC ACTION OF 5-FLUOROURACIL (5FU)
    ZACCARO, L
    ROSSI, AM
    BATTOLLA, R
    MUTATION RESEARCH, 1987, 181 (02): : 320 - 320
  • [10] Combined radiotherapy, 5-Fluorouracil (5FU) continuous infusion and weekly Oxaliplatin in advanced rectal cancer: Phase I study
    Francois, Eric D.
    Ychou, Marc
    Ducreux, Michel
    Bertheault-Cvitkovic, Frederique
    Giovannini, Marc
    Conroy, Thierry
    Lemansk, Claire
    Thomas, Oliver
    Mari, Veronique
    ANNALS OF ONCOLOGY, 2004, 15 : 96 - 97
12345